An investigation for investors in Esperion Therapeutics Inc (NASDAQ:ESPR) shares over potential securities laws violations by Esperion Therapeutics was announced and NASDAQ:ESPR stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 10/19/2015 -- An investigation for shareholders in NASDAQ:ESPR shares over potential securities laws violations by Esperion Therapeutics in connection certain financial statements was announced.
Investors who purchased shares of Esperion Therapeutics Inc (NASDAQ:ESPR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Esperion Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On September 28, 2015, Esperion Therapeutics Inc provided an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the U.S. Food and Drug Administration ("FDA"). Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) declined to as low as $18.07 per share on September 29, 2105.
On October 16, 2015, NASDAQ:ESPR shares closed at $23.11 per share.
Those who purchased shares of Esperion Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego